MitoQ for Pre-eclampsia

(MAVEN Trial)

This trial tests whether MitoQ, a special type of antioxidant, can improve placental health and prolong pregnancy in women with preeclampsia, a serious pregnancy complication affecting blood flow. The researchers aim to determine if MitoQ can restore blood vessel function and improve outcomes for both mothers and babies. Pregnant participants diagnosed with preeclampsia (with or without severe features) who plan for continued management rather than immediate delivery might be suitable for this trial.

As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could lead to better treatments for preeclampsia.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Mitoquinol Mesylate, or MitoQ, has been tested for safety in humans. This antioxidant is already in trials for other health issues. Studies suggest that MitoQ can help prevent preeclampsia if administered later in pregnancy. However, using it too early might increase the risk of preeclampsia, so timing is crucial.

Unlike the standard treatments for pre-eclampsia, which often focus on managing symptoms with blood pressure medications like labetalol or nifedipine, Mitoquinol Mesylate offers a new approach by directly targeting oxidative stress. This treatment is unique because it uses MitoQ, a powerful antioxidant designed to penetrate mitochondria, potentially reducing oxidative damage at the cellular level. Researchers are excited about MitoQ because it may address the root cause of some complications associated with pre-eclampsia, potentially improving outcomes for both mothers and their babies.

Research has shown that Mitoquinol Mesylate, or MitoQ, may help treat preeclampsia. In this trial, some participants with preeclampsia will receive MitoQ, while others will receive a placebo. Studies have found that this antioxidant can improve blood vessel function and support healthier placentas. For instance, MitoQ proved more effective than other treatments at reducing harmful hydrogen peroxide levels in cells. Additionally, earlier studies showed that MitoQ could lower high blood pressure in pregnant women when used later in pregnancy. These findings suggest that MitoQ may help safely extend pregnancy and improve health outcomes for mothers and babies.¹²⁴⁶⁷